As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of ...

Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared ...

Q4 Results Today May 30, 2025, Highlights: Find all the Q4 results 2025 updates for Apollo Hospitals, Vodafone Idea, Sun TV Network, Bajaj Holdings, Inox Wind Energy, AstraZeneca Pharma and more here.

Vepdegestrant significantly improved outcomes for certain patients with ER-positive, HER2-negative advanced breast cancer ...

Pfizer and Arvinas' experimental treatment significantly extends progression-free survival in breast cancer patients with ...

(RTTNews) - Arvinas Inc. (ARVN) and Pfizer Inc. (PFE) announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrog ...

Pfizer (PFE) and Arvinas (ARVN) aim to seek FDA approval for thier breast cancer therapy vepdegestrant in H2 2025. Read more ...

New breast cancer drug vepdegestrant shows promising results in increasing survival rates for patients with ESR1 mutations.

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...